Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

QRxPharma Announces NDA Filing for MoxDuo® IR

July 18, 2011 By Bio-Medicine.Org

SYDNEY and BEDMINSTER, N.J., July 18, 2011 /PRNewswire/
— QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today
initiation of the New Drug Application (NDA) approval process for
MoxDuo IR with the United States Food and Drug Administration
(FDA).  This NDA submission sets the stage for the regulatory
approval process for MoxDuo IR for the treatment of moderate to
severe acute pain, a $2.5 billion segment of the $8 billion spent
annually on prescription opioids in the US. MoxDuo IR, an
immediate-release Dual Opioid® pain therapy, is a patented 3:2
fixed ratio combination of morphine and oxycodone.

“In just four years, we have successfully moved MoxDuo IR
through clinical trials and NDA submission by demonstrating its
effectiveness and safety. Achievement of this milestone clearly
establishes the value of this Dual Opioid product to patients and
prescribers as well as potential partners,” said Dr. John Holaday,
Managing Director and Chief Executive Officer, QRxPharma. “The
timeframe and capital efficient manner in which these milestones
were achieved are impressive accomplishments compared to
conventional industry development and cost benchmarks.”

This NDA submission is based on a full clinical and
manufacturing program for MoxDuo IR. As agreed with the FDA, the
NDA for MoxDuo IR is being submitted under 505(b)(2) regulations
wherein approval for a new drug may be obtained more efficiently
because the approval process can rely upon historical data
regarding its’ already approved components. A 505(b)(2) approval
also provides commercial benefits because, in parallel to patents
which cover MoxDuo until 2029, it affords to the sponsor additional
regulatory market exclusivity, allowing companies to develop a
marketing strategy with a brand consumers recognize and may prefer
in a potentially wide-open market.

As agreed with the FDA during its pre-NDA meeting with the
Company in March, 2011, the NDA manufacturing section fil

‘/>”/>

SOURCE

Related Articles Read More >

CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech